Serum ferritin observations in beta thalassemia major patients with dermatological manifestation
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242912Keywords:
Asgar Ali Hospital, Dhaka, BangladeshAbstract
Background: Beta thalassemia major is a severe inherited blood disorder requiring regular blood transfusions, leading to chronic iron overload. This study aims to analyze serum ferritin levels and their association with dermatological manifestations in patients with beta thalassemia major in Bangladesh.
Methods: This cross-sectional observational study was conducted at the Department of Transfusion Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka, from March 2019 to August 2021. A purposive sample of 60 beta thalassemia major patients was selected based on specific inclusion and exclusion criteria. Data collection included detailed medical histories, dermatological examinations, and laboratory investigations for serum ferritin levels. Statistical analysis was performed using statistical package for the social sciences (SPSS)-27.
Results: Among the participants, 26.67% were aged 10 years or younger, and 46.67% were aged 11-20 years. The gender distribution was 43.33% male and 56.67% female. The mean hemoglobin level was 6.17±0.95 g/dl, with 75.00% of participants exhibiting extremely high serum ferritin levels (>1000 ng/ml). Dermatological manifestations included hyperpigmentation (50.00%), xerosis (46.67%), and pallor (26.67%). Significant associations were found between high serum ferritin levels and conditions such as hyperpigmentation (p=0.028) and xerosis (p<0.001).
Conclusions: The study underscores the critical need for regular monitoring and effective management of serum ferritin levels to mitigate dermatological and systemic complications in beta thalassemia major patients. Effective chelation therapy is essential to reduce the iron burden and improve patient outcomes.
References
Kabir AL, Irshadullah NM, Rahman M. Cardiac Complications in Non-Transfusion Dependent Thalassaemia. Haematol J Bangladesh. 2019;3(1):24-7.
Noor FA, Sultana N, Bhuyan GS, Islam MT, Hossain M, Sarker SK, et al. Nationwide carrier detection and molecular characterization of β-thalassemia and hemoglobin E variants in Bangladeshi population. Orphanet J Rare Dis. 2020;15(1):15.
Bhuiyan R, Aklima J, Emran T, Dash R, Palit S. A study of the prevalence of thalassemia and its correlation with liver function test in different age and sex group in the Chittagong district of Bangladesh. J Basic Clin Pharma. 2012;3(4):352.
Shahid Z, Hassan S, Ghazanfar S, Kaneez M, Khan MS, Tariq HT, et al. Investigating the Role of Ferritin in Determining Sexual Underdevelopment in Beta-Thalassemia Major Patients: A Cross-Sectional Analysis From Pakistan. Cureus. 2021;13.
Ibrahim AS, El-Fatah AHA, El-Halim AFA, Mohamed FF. Serum Ferritin Levels and Other Associated Parameters with Diabetes Mellitus in Adult Patients Suffering from Beta Thalassemia Major. JBM. 2023;14:67-81.
Belhoul KM, Bakir ML, Saned MS, Kadhim AMA, Musallam KM, Taher AT. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol. 2012;91(7):1107-14.
Bhalodiya VR, Valiya LG, Mehta NA, Padhariya BB. Correlation of serum ferritin level in transfusion-dependant thalassemia major patients: a study at a medical college affiliated hospital in Gujarat region. Int J Contemp Pediatr. 2023;10(3):330-3.
Roy K, Das S, Dutta A, Mandal R. Dermatological manifestations in beta thalassemia major patients between 2 to 12 years and their relation with serum ferritine level. J Pediatr Assoc India. 2018;7(3):149.
Zulfiqar Z, Kanwal A, Chaudhry M, Aadil M, Qaiser S, Malik A, et al. Cutaneous Manifestations in Patients with Beta-Thalassemia Major. J Mother Child. 2023;27(1):142-6.
Vinchi F, Vercellotti GM, Belcher JD, Fibach E, Zreid H, Rasras R, et al. Systemic Heme and Iron Overload Results in Depletion of Serum Hemopexin, Haptoglobin and Transferrin and Correlates with Markers of Endothelial Activation and Lipid Oxidation in Beta Thalassemia Major and Intermedia. Blood. 2016;128(22):2469.
Pearson HA, Cohen AR, Giardina PJ, Kazazian HH. The changing profile of homozygous beta-thalassemia: demography, ethnicity, and age distribution of current North American patients and changes in two decades. Pediatrics. 1996;97(3):352-6.
Saka N, Şükür M, Bundak R, Anak S, Neyzi O, Gedikoglu G. Growth and Puberty in Thalassemia Major. J Pediatr Endocrinol Metabolism. 1995;8(3):181-6.
Al-Kherbash HA, Al-Awdi A, Hasan NS. Pattern and clinical profile of thalassemia among pediatric patients attending the Yemeni Society Centers for Thalassemia and Genetic Blood Disorders in Yemen. Scientific Jo Al-Azhar Med Faculty Girls. 2017;1:43-56.
Koreti DS, Gaur DBK, Das DG, Gaur DA. Study of Serum ferritin levels in β-Thalassemia major children. Pediatric Rev. 2018;5(6):308-13.
Riaz H, Riaz T, Khan MU, Aziz S, Ullah F, Rehman A, et al. Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan. BMC Res Notes. 2011;4(1):287.
Dogramaci AC, Savas N, Ozer B, Duran N. Skin diseases in patients with beta-thalassemia major. Int J Dermatol. 2009;48(10):1057-61.
Skandalis K, Vlachos C, Pliakou X, Gaitanis G, Kapsali E, Bassukas ID. Higher Serum Ferritin Levels Correlate with an Increased Risk of Cutaneous Morbidity in Adult Patients with β-Thalassemia: A Single-Center Retrospective Study. Acta Haematologica. 2015;135(2):124-30.
Eshaqh-hosseini SK, Jafari-Koshki T, Arsang-Jang S, Shapouri J. Endocrinopathy Complications and the Role of Serum Ferritin as A Marker of Endocrinopathy Prediction in Patients With Beta-Thalassemia Major. Adv Human Biol. 2018;8(3):169.
